Prostate Gene Expression Changes Associated with BPH

与 BPH 相关的前列腺基因表达变化

• 批准号: 6577473
• 负责人: Kevin M Slawin
• 金额: $ 45.15万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2005-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6577473
• 关键词: RNase protection assay; benign prostate hyperplasia; biomarker; clinical research; enzyme inhibitors; gene expression; genetic markers; genetic transcription; human subject; human tissue; immunocytochemistry; laser capture microdissection; longitudinal human study; mass screening; messenger RNA; microarray technology; neoplasm /cancer genetics; pathologic process; polymerase chain reaction; prognosis; prostate; prostate specific antigen; prostate surgery; proteomics; testosterone 5 alpha reductase; tissue resource /registry; western blottings

DESCRIPTION (provided by applicant): Through this application, Baylor College of Medicine responds to RFA: DK-02-017, MTOPS Prostate Samples Analysis Consortium (MPSA). The Baylor Prostate Center proposes to serve as a Biomarker Unit within the MPSA consortium, which will work cooperatively with the other Biomarker Units, the Pathology Coordinating Center, and the NIDDK Project Coordinator to perform basic and translational research on biomarkers for BPH. The PI, Kevin M. Slaw/n, M.D., Director of the Baylor Prostate Center, recruited and managed 200 patients on the MTOPS trial over its seven-year duration. The co-investigators encompass broad interests and expertise in both clinical and basic research in benign prostatic hyperplasia (BPH), molecular epidemiology, biomarkers research, genetic and tissue microarray technology, cell signaling, and sophisticated data mining and statistical analysis of complex biologic data. Drawing from his extensive BPH clinical trials experience and with the resource management skills gained as co-Director of both the Biopsy and the Basic Tissue Research Committees of the MTOPS trial, as the Serum Bank director and member of the Resource Allocation Committee of the Baylor SPORE in Prostate Cancer, and as director of Baylor's Prostate Cancer Screening Program for the past eight years, the PI has the requisite administrative, clinical and basic research experience in BPH and biomarker development and validation to lead this center. Furthermore, the considerable tissue resources available through BPH-sub-studies of the Baylor SPORE in Prostate Cancer, and the expertise in tissue harvesting, cataloguing and banking, and in tissue microarray development and production will serve as a valuable resource for biomarker validation prior to testing on the invaluable and limited MTOPS tissue for the Baylor Center, as well as, for the other MPSA consortium members. Our large prostate cancer screening serum bank, containing frozen sera obtained through a yearly program, contains serial frozen serum samples and clinical data including IPSS, DRE estimated prostate volume, and medical and surgical treatment history for BPH on over 10,000 patients spanning a decade of follow-up. Serum markers that correlate with the presence and severity of BPH or that predict progression or response to medical therapy, identified either by the Baylor Biomarkers Center, or by other Centers could be validated in a Phase II study with these resources, allowing only the best markers for progression to evaluation in Phase III studies using the exhaustible MTOPS serum and tissue bank resources. Through the efforts of this RFA proposal, the Baylor MPSA Center, along with the other centers, the Biostatistics Center and the NIDDK, hopes to answer identify and validate much needed new biomarkers for the detection of BPH and the assessment of risk for disease progression, as well as to gain insight into the molecular correlates that determine response to medical therapies, primarily a-blockers and 5a-reductase inhibitors for this disease.

描述（由申请人提供）： 通过此应用，贝勒医学院对RFA：DK-02-017，MTOPS样本分析联盟（MPSA）做出了回应。 Baylor前列腺中心建议在MPSA联盟中充当生物标志物单元，该单元将与其他生物标志物单元，病理协调中心和NIDDK项目协调员合作，以对BPH进行生物标志物进行基本和翻译研究。 Baylor前列腺中心主任PI，Kevin M. Slaw/N，医学博士，在MTOPS试验的7年期间，在MTOPS试验中招募并管理了200名患者。共同研究者包括良性前列腺增生（BPH），分子流行病学，生物标志物研究，遗传和组织微阵列技术，细胞信号传导以及复杂数据挖掘以及复杂生物学数据的复杂数据挖掘以及复杂生物学数据的统计分析的临床和基础研究方面的广泛兴趣和专业知识。从他的丰富BPH临床试验经验中汲取灵感以及作为MTOPS试验的活检和基本组织研究委员会的共同指导的资源管理技能，作为血清银行的主任和Baylor Spore的资源分配委员会成员的前列腺癌，以及贝勒过去的八年的前列典礼和Bios biess bios the PISITE the PISITE the PISITE the PISITE the PISITE the BLES INTICE，PIS的必要经验，和验证以领导该中心。此外，可通过BPH孢子的BPH-SUB研究可获得的大量组织资源，以及组织收集，分类和银行的组织收集，分类和银行的专业知识，以及组织微阵列的开发和生产的宝贵资源，用于在对MTOP的MTOPS组织中进行测试，并在Baylor的MTOP组织中进行生物标记验证，以及Baylor的MTA，以及其他以及其他人的中心。我们的大型前列腺癌筛查血清库，其中包含通过年度程序获得的冷冻血清，其中包含串行冷冻的血清样品和临床数据，包括IPS，DRE估计的前列腺量，前列腺量以及BPH的医学和外科手术治疗史，超过10,000名患者跨越了十年的随访。与BPH的存在和严重性相关的血清标志物或预测由Baylor生物标志物中心确定的进展或反应的血清标志物，或者通过这些资源的II阶段研究来验证其他中心，仅允许使用耗尽的MTOPS Serum Serum和Tissue Bank Resources在III阶段进行评估的最佳标记。 Through the efforts of this RFA proposal, the Baylor MPSA Center, along with the other centers, the Biostatistics Center and the NIDDK, hopes to answer identify and validate much needed new biomarkers for the detection of BPH and the assessment of risk for disease progression, as well as to gain insight into the molecular correlates that determine response to medical therapies, primarily a-blockers and 5a-reductase inhibitors for this disease.